General Announcement::No significant clinical benefit with Umifenovir addition in COVID-19 treatment

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
09-Oct-2020 22:07:15
Status
New
Announcement Sub Title
No significant clinical benefit with Umifenovir addition in COVID-19 treatment
Announcement Reference
SG201009OTHRD25L
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
09/10/2020 00:00:00
Description (Please provide a detailed description of the event in the box below)
No significant clinical benefit with Umifenovir addition in COVID-19 treatment: Glenmark clinical study

Attachments

SGX_PR_09102020.pdf
Total size =929K